Status:
RECRUITING
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Lead Sponsor:
University of California, Los Angeles
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of diabetes and obesity. Thei...
Detailed Description
Background and Rationale: Glucagon like peptide (GLP-1) agonists, such as liraglutide, exenatide, and semaglutide, have been increasingly used as a medication to address the current twin epidemics of...
Eligibility Criteria
Inclusion
- Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
- \>18 years of age and willing to participate
- Male or post-menopausal females
Exclusion
- History of prior neck surgery and /or neck irradiation
- Use of beta blocker agents
- Use of any other glucose lowering medication
- History of neuropathic disorders (e.g. diabetic neuropathy)
- Diabetic patients
- Individuals without normal thyroid function
- Individuals with cancer
- Any significant chronic disease or renal, hepatic or endocrine disease
- Current smokers
- Inability of patient to provide consent either for medical reasons or psychiatric reasons
Key Trial Info
Start Date :
February 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05419726
Start Date
February 1 2023
End Date
February 1 2026
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Health
Los Angeles, California, United States, 90095